VNRX
Volitionrx·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Stock Price Surged Significantly
Significant Inflow of Main Funds
Consensus Rating "Strong Buy"
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VNRX
Volitionrx Limited
A developer of blood-based diagnostic tests used for detecting and diagnosing cancer
Healthcare Equipment and Supplies
09/24/1998
02/06/2015
American Stock Exchange
85
12-31
Common stock
1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014
--
Volitionrx Limited was incorporated under the laws of the State of Delaware on September 24, 1998. The company is a clinical-stage life sciences company dedicated to developing blood-based diagnostic tests for the detection and diagnosis of cancer and other diseases to meet the needs of accurate, fast, inexpensive, scalable diagnostic tests. To date, the company has developed 20 blood assays using its Nucleosomics biomarker-based technology platform, which can be used alone or in combination to generate cancer-specific blood test-based profiles.
Earnings Call
Q1/2025
Estimate EPS-0.05
Actual EPS-0.06
Estimate Revenue1.08M
Actual Revenue250.00K
VolitionRx's Q1 2025: Unraveling Contradictions in Feline Cancer Test Progress and Financial Sustainability
May 02,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.05
Actual EPS-0.05
Estimate Revenue715.59K
Actual Revenue627.28K
VolitionRx Q3 2025: Contradictions Emerge on Werfen Partnership Revenue, Cost-Cutting Strategy, and Lung Cancer Study Progress
Nov 14,2025 01:04
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VNRX has released its 2025 Q3 earnings. EPS was reported at -0.05, versus the expected -0.05, meeting expectations. The chart below visualizes how VNRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VNRX has released its 2025 Q3 earnings report, with revenue of 627.28K, reflecting a YoY change of 32.19%, and net profit of -5.41M, showing a YoY change of 7.82%. The Sankey diagram below clearly presents VNRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
